table of content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.4.1 North America Market States and Outlook (2023-2028)
1.4.2 East Asia Market States and Outlook (2023-2028)
1.4.3 Europe Market States and Outlook (2023-2028)
1.4.4 South Asia Market States and Outlook (2023-2028)
1.4.5 Southeast Asia Market States and Outlook (2023-2028)
1.4.6 Middle East Market States and Outlook (2023-2028)
1.4.7 Africa Market States and Outlook (2023-2028)
1.4.8 Oceania Market States and Outlook (2023-2028)
1.4.9 South America Market States and Outlook (2023-2028)
1.5 Global Autoimmune Drugs Market Size Analysis from 2023 to 2028
1.5.1 Global Autoimmune Drugs Market Size Analysis from 2023 to 2028 by Consumption Volume
1.5.2 Global Autoimmune Drugs Market Size Analysis from 2023 to 2028 by Value
1.5.3 Global Autoimmune Drugs Price Trends Analysis from 2023 to 2028
1.6 COVID-19 Outbreak: Autoimmune Drugs Industry Impact
Chapter 2 Global Autoimmune Drugs Competition by Types, Applications, and Top Regions and Countries
2.1 Global Autoimmune Drugs (Volume and Value) by Type
2.1.1 Global Autoimmune Drugs Consumption and Market Share by Type (2017-2022)
2.1.2 Global Autoimmune Drugs Revenue and Market Share by Type (2017-2022)
2.2 Global Autoimmune Drugs (Volume and Value) by Application
2.2.1 Global Autoimmune Drugs Consumption and Market Share by Application (2017-2022)
2.2.2 Global Autoimmune Drugs Revenue and Market Share by Application (2017-2022)
2.3 Global Autoimmune Drugs (Volume and Value) by Regions
2.3.1 Global Autoimmune Drugs Consumption and Market Share by Regions (2017-2022)
2.3.2 Global Autoimmune Drugs Revenue and Market Share by Regions (2017-2022)
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.1.1 2017-2022 Global Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis
3.1.2 2017-2022 Major Manufacturers Performance and Market Share
3.2 Regional Production Market Analysis
3.2.1 2017-2022 Regional Market Performance and Market Share
3.2.2 North America Market
3.2.3 East Asia Market
3.2.4 Europe Market
3.2.5 South Asia Market
3.2.6 Southeast Asia Market
3.2.7 Middle East Market
3.2.8 Africa Market
3.2.9 Oceania Market
3.2.10 South America Market
3.2.11 Rest of the World Market
Chapter 4 Global Autoimmune Drugs Sales, Consumption, Export, Import by Regions (2017-2022)
4.1 Global Autoimmune Drugs Consumption by Regions (2017-2022)
4.2 North America Autoimmune Drugs Sales, Consumption, Export, Import (2017-2022)
4.3 East Asia Autoimmune Drugs Sales, Consumption, Export, Import (2017-2022)
4.4 Europe Autoimmune Drugs Sales, Consumption, Export, Import (2017-2022)
4.5 South Asia Autoimmune Drugs Sales, Consumption, Export, Import (2017-2022)
4.6 Southeast Asia Autoimmune Drugs Sales, Consumption, Export, Import (2017-2022)
4.7 Middle East Autoimmune Drugs Sales, Consumption, Export, Import (2017-2022)
4.8 Africa Autoimmune Drugs Sales, Consumption, Export, Import (2017-2022)
4.9 Oceania Autoimmune Drugs Sales, Consumption, Export, Import (2017-2022)
4.10 South America Autoimmune Drugs Sales, Consumption, Export, Import (2017-2022)
Chapter 5 North America Autoimmune Drugs Market Analysis
5.1 North America Autoimmune Drugs Consumption and Value Analysis
5.1.1 North America Autoimmune Drugs Market Under COVID-19
5.2 North America Autoimmune Drugs Consumption Volume by Types
5.3 North America Autoimmune Drugs Consumption Structure by Application
5.4 North America Autoimmune Drugs Consumption by Top Countries
5.4.1 United States Autoimmune Drugs Consumption Volume from 2017 to 2022
5.4.2 Canada Autoimmune Drugs Consumption Volume from 2017 to 2022
5.4.3 Mexico Autoimmune Drugs Consumption Volume from 2017 to 2022
Chapter 6 East Asia Autoimmune Drugs Market Analysis
6.1 East Asia Autoimmune Drugs Consumption and Value Analysis
6.1.1 East Asia Autoimmune Drugs Market Under COVID-19
6.2 East Asia Autoimmune Drugs Consumption Volume by Types
6.3 East Asia Autoimmune Drugs Consumption Structure by Application
6.4 East Asia Autoimmune Drugs Consumption by Top Countries
6.4.1 China Autoimmune Drugs Consumption Volume from 2017 to 2022
6.4.2 Japan Autoimmune Drugs Consumption Volume from 2017 to 2022
6.4.3 South Korea Autoimmune Drugs Consumption Volume from 2017 to 2022
Chapter 7 Europe Autoimmune Drugs Market Analysis
7.1 Europe Autoimmune Drugs Consumption and Value Analysis
7.1.1 Europe Autoimmune Drugs Market Under COVID-19
7.2 Europe Autoimmune Drugs Consumption Volume by Types
7.3 Europe Autoimmune Drugs Consumption Structure by Application
7.4 Europe Autoimmune Drugs Consumption by Top Countries
7.4.1 Germany Autoimmune Drugs Consumption Volume from 2017 to 2022
7.4.2 UK Autoimmune Drugs Consumption Volume from 2017 to 2022
7.4.3 France Autoimmune Drugs Consumption Volume from 2017 to 2022
7.4.4 Italy Autoimmune Drugs Consumption Volume from 2017 to 2022
7.4.5 Russia Autoimmune Drugs Consumption Volume from 2017 to 2022
7.4.6 Spain Autoimmune Drugs Consumption Volume from 2017 to 2022
7.4.7 Netherlands Autoimmune Drugs Consumption Volume from 2017 to 2022
7.4.8 Switzerland Autoimmune Drugs Consumption Volume from 2017 to 2022
7.4.9 Poland Autoimmune Drugs Consumption Volume from 2017 to 2022
Chapter 8 South Asia Autoimmune Drugs Market Analysis
8.1 South Asia Autoimmune Drugs Consumption and Value Analysis
8.1.1 South Asia Autoimmune Drugs Market Under COVID-19
8.2 South Asia Autoimmune Drugs Consumption Volume by Types
8.3 South Asia Autoimmune Drugs Consumption Structure by Application
8.4 South Asia Autoimmune Drugs Consumption by Top Countries
8.4.1 India Autoimmune Drugs Consumption Volume from 2017 to 2022
8.4.2 Pakistan Autoimmune Drugs Consumption Volume from 2017 to 2022
8.4.3 Bangladesh Autoimmune Drugs Consumption Volume from 2017 to 2022
Chapter 9 Southeast Asia Autoimmune Drugs Market Analysis
9.1 Southeast Asia Autoimmune Drugs Consumption and Value Analysis
9.1.1 Southeast Asia Autoimmune Drugs Market Under COVID-19
9.2 Southeast Asia Autoimmune Drugs Consumption Volume by Types
9.3 Southeast Asia Autoimmune Drugs Consumption Structure by Application
9.4 Southeast Asia Autoimmune Drugs Consumption by Top Countries
9.4.1 Indonesia Autoimmune Drugs Consumption Volume from 2017 to 2022
9.4.2 Thailand Autoimmune Drugs Consumption Volume from 2017 to 2022
9.4.3 Singapore Autoimmune Drugs Consumption Volume from 2017 to 2022
9.4.4 Malaysia Autoimmune Drugs Consumption Volume from 2017 to 2022
9.4.5 Philippines Autoimmune Drugs Consumption Volume from 2017 to 2022
9.4.6 Vietnam Autoimmune Drugs Consumption Volume from 2017 to 2022
9.4.7 Myanmar Autoimmune Drugs Consumption Volume from 2017 to 2022
Chapter 10 Middle East Autoimmune Drugs Market Analysis
10.1 Middle East Autoimmune Drugs Consumption and Value Analysis
10.1.1 Middle East Autoimmune Drugs Market Under COVID-19
10.2 Middle East Autoimmune Drugs Consumption Volume by Types
10.3 Middle East Autoimmune Drugs Consumption Structure by Application
10.4 Middle East Autoimmune Drugs Consumption by Top Countries
10.4.1 Turkey Autoimmune Drugs Consumption Volume from 2017 to 2022
10.4.2 Saudi Arabia Autoimmune Drugs Consumption Volume from 2017 to 2022
10.4.3 Iran Autoimmune Drugs Consumption Volume from 2017 to 2022
10.4.4 United Arab Emirates Autoimmune Drugs Consumption Volume from 2017 to 2022
10.4.5 Israel Autoimmune Drugs Consumption Volume from 2017 to 2022
10.4.6 Iraq Autoimmune Drugs Consumption Volume from 2017 to 2022
10.4.7 Qatar Autoimmune Drugs Consumption Volume from 2017 to 2022
10.4.8 Kuwait Autoimmune Drugs Consumption Volume from 2017 to 2022
10.4.9 Oman Autoimmune Drugs Consumption Volume from 2017 to 2022
Chapter 11 Africa Autoimmune Drugs Market Analysis
11.1 Africa Autoimmune Drugs Consumption and Value Analysis
11.1.1 Africa Autoimmune Drugs Market Under COVID-19
11.2 Africa Autoimmune Drugs Consumption Volume by Types
11.3 Africa Autoimmune Drugs Consumption Structure by Application
11.4 Africa Autoimmune Drugs Consumption by Top Countries
11.4.1 Nigeria Autoimmune Drugs Consumption Volume from 2017 to 2022
11.4.2 South Africa Autoimmune Drugs Consumption Volume from 2017 to 2022
11.4.3 Egypt Autoimmune Drugs Consumption Volume from 2017 to 2022
11.4.4 Algeria Autoimmune Drugs Consumption Volume from 2017 to 2022
11.4.5 Morocco Autoimmune Drugs Consumption Volume from 2017 to 2022
Chapter 12 Oceania Autoimmune Drugs Market Analysis
12.1 Oceania Autoimmune Drugs Consumption and Value Analysis
12.2 Oceania Autoimmune Drugs Consumption Volume by Types
12.3 Oceania Autoimmune Drugs Consumption Structure by Application
12.4 Oceania Autoimmune Drugs Consumption by Top Countries
12.4.1 Australia Autoimmune Drugs Consumption Volume from 2017 to 2022
12.4.2 New Zealand Autoimmune Drugs Consumption Volume from 2017 to 2022
Chapter 13 South America Autoimmune Drugs Market Analysis
13.1 South America Autoimmune Drugs Consumption and Value Analysis
13.1.1 South America Autoimmune Drugs Market Under COVID-19
13.2 South America Autoimmune Drugs Consumption Volume by Types
13.3 South America Autoimmune Drugs Consumption Structure by Application
13.4 South America Autoimmune Drugs Consumption Volume by Major Countries
13.4.1 Brazil Autoimmune Drugs Consumption Volume from 2017 to 2022
13.4.2 Argentina Autoimmune Drugs Consumption Volume from 2017 to 2022
13.4.3 Columbia Autoimmune Drugs Consumption Volume from 2017 to 2022
13.4.4 Chile Autoimmune Drugs Consumption Volume from 2017 to 2022
13.4.5 Venezuela Autoimmune Drugs Consumption Volume from 2017 to 2022
13.4.6 Peru Autoimmune Drugs Consumption Volume from 2017 to 2022
13.4.7 Puerto Rico Autoimmune Drugs Consumption Volume from 2017 to 2022
13.4.8 Ecuador Autoimmune Drugs Consumption Volume from 2017 to 2022
Chapter 14 Company Profiles and Key Figures in Autoimmune Drugs Business
14.1 AbbVie
14.1.1 AbbVie Company Profile
14.1.2 AbbVie Autoimmune Drugs Product Specification
14.1.3 AbbVie Autoimmune Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.2 Johnson & Johnson
14.2.1 Johnson & Johnson Company Profile
14.2.2 Johnson & Johnson Autoimmune Drugs Product Specification
14.2.3 Johnson & Johnson Autoimmune Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.3 Biogen
14.3.1 Biogen Company Profile
14.3.2 Biogen Autoimmune Drugs Product Specification
14.3.3 Biogen Autoimmune Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.4 Amgen
14.4.1 Amgen Company Profile
14.4.2 Amgen Autoimmune Drugs Product Specification
14.4.3 Amgen Autoimmune Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.5 Pfizer
14.5.1 Pfizer Company Profile
14.5.2 Pfizer Autoimmune Drugs Product Specification
14.5.3 Pfizer Autoimmune Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.6 F. Hoffmann-La Roche
14.6.1 F. Hoffmann-La Roche Company Profile
14.6.2 F. Hoffmann-La Roche Autoimmune Drugs Product Specification
14.6.3 F. Hoffmann-La Roche Autoimmune Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.7 AstraZeneca
14.7.1 AstraZeneca Company Profile
14.7.2 AstraZeneca Autoimmune Drugs Product Specification
14.7.3 AstraZeneca Autoimmune Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.8 GSK
14.8.1 GSK Company Profile
14.8.2 GSK Autoimmune Drugs Product Specification
14.8.3 GSK Autoimmune Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.9 Merck
14.9.1 Merck Company Profile
14.9.2 Merck Autoimmune Drugs Product Specification
14.9.3 Merck Autoimmune Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.10 Boehringer Ingelheim
14.10.1 Boehringer Ingelheim Company Profile
14.10.2 Boehringer Ingelheim Autoimmune Drugs Product Specification
14.10.3 Boehringer Ingelheim Autoimmune Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.11 Eli Lilly
14.11.1 Eli Lilly Company Profile
14.11.2 Eli Lilly Autoimmune Drugs Product Specification
14.11.3 Eli Lilly Autoimmune Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.12 Novartis
14.12.1 Novartis Company Profile
14.12.2 Novartis Autoimmune Drugs Product Specification
14.12.3 Novartis Autoimmune Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.13 Sanofi
14.13.1 Sanofi Company Profile
14.13.2 Sanofi Autoimmune Drugs Product Specification
14.13.3 Sanofi Autoimmune Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.14 Takeda Pharmaceuticals
14.14.1 Takeda Pharmaceuticals Company Profile
14.14.2 Takeda Pharmaceuticals Autoimmune Drugs Product Specification
14.14.3 Takeda Pharmaceuticals Autoimmune Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.15 Vertex Pharmaceuticals
14.15.1 Vertex Pharmaceuticals Company Profile
14.15.2 Vertex Pharmaceuticals Autoimmune Drugs Product Specification
14.15.3 Vertex Pharmaceuticals Autoimmune Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.16 Eisai
14.16.1 Eisai Company Profile
14.16.2 Eisai Autoimmune Drugs Product Specification
14.16.3 Eisai Autoimmune Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.17 Lexicon Pharmaceuticals
14.17.1 Lexicon Pharmaceuticals Company Profile
14.17.2 Lexicon Pharmaceuticals Autoimmune Drugs Product Specification
14.17.3 Lexicon Pharmaceuticals Autoimmune Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.18 KaloBios Pharmaceuticals
14.18.1 KaloBios Pharmaceuticals Company Profile
14.18.2 KaloBios Pharmaceuticals Autoimmune Drugs Product Specification
14.18.3 KaloBios Pharmaceuticals Autoimmune Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.19 Can-Fite BioPharma
14.19.1 Can-Fite BioPharma Company Profile
14.19.2 Can-Fite BioPharma Autoimmune Drugs Product Specification
14.19.3 Can-Fite BioPharma Autoimmune Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.20 Antares Pharma
14.20.1 Antares Pharma Company Profile
14.20.2 Antares Pharma Autoimmune Drugs Product Specification
14.20.3 Antares Pharma Autoimmune Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.21 Acorda Therapeutics
14.21.1 Acorda Therapeutics Company Profile
14.21.2 Acorda Therapeutics Autoimmune Drugs Product Specification
14.21.3 Acorda Therapeutics Autoimmune Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
Chapter 15 Global Autoimmune Drugs Market Forecast (2023-2028)
15.1 Global Autoimmune Drugs Consumption Volume, Revenue and Price Forecast (2023-2028)
15.1.1 Global Autoimmune Drugs Consumption Volume and Growth Rate Forecast (2023-2028)
15.1.2 Global Autoimmune Drugs Value and Growth Rate Forecast (2023-2028)
15.2 Global Autoimmune Drugs Consumption Volume, Value and Growth Rate Forecast by Region (2023-2028)
15.2.1 Global Autoimmune Drugs Consumption Volume and Growth Rate Forecast by Regions (2023-2028)
15.2.2 Global Autoimmune Drugs Value and Growth Rate Forecast by Regions (2023-2028)
15.2.3 North America Autoimmune Drugs Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.4 East Asia Autoimmune Drugs Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.5 Europe Autoimmune Drugs Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.6 South Asia Autoimmune Drugs Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.7 Southeast Asia Autoimmune Drugs Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.8 Middle East Autoimmune Drugs Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.9 Africa Autoimmune Drugs Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.10 Oceania Autoimmune Drugs Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.11 South America Autoimmune Drugs Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.3 Global Autoimmune Drugs Consumption Volume, Revenue and Price Forecast by Type (2023-2028)
15.3.1 Global Autoimmune Drugs Consumption Forecast by Type (2023-2028)
15.3.2 Global Autoimmune Drugs Revenue Forecast by Type (2023-2028)
15.3.3 Global Autoimmune Drugs Price Forecast by Type (2023-2028)
15.4 Global Autoimmune Drugs Consumption Volume Forecast by Application (2023-2028)
15.5 Autoimmune Drugs Market Forecast Under COVID-19
Chapter 16 Conclusions
Research Methodology
